A new sandwich-type enzyme-linked immunosorbent assay for quantifying glycocalicin, a proteolytic fragment of platelet membrane glycoprotein Ib, is described. The assay is based on the use of two monoclonal antibodies raised against glycoprotein lb and involves the avidinbiotin technique. The detection limit is 7 p.g/L and the range of glycocalicin determined in plasma is 0.01 to 1 mg/L. Assay time is 2 h. The intra-assay CV ranged from 3.6% to 5.2%, the interassay CV from 5.4% to 8.0%. Analytical recovery of purified glycocalicin added to a plasma pool averaged 96%. In 36 healthy subjects, the mean glycocalicin concentration in plasma was 0.36 (SD 0.07) mgIL (2.7 nmol/L). We conclude that this assay is suitable for measuring glycocalicin in plasma and is also more sensitive and precise than the previously published immunoassays based on competitive binding assay.
glycoprotein lb plays an important role in primary hemostasis by serving as the receptor for von Willebrand's factor bound to the subendotheliuin of damaged blood vessels (1) (2) (3) . It also binds thrombin (4) It consists of two disulfide-linked subunits, a-subunit (Mr 143 000) and /3-subunit (Mr 23 000) (6).
Glycocalicin is a carbohydrate-rich, hydrophilic fragment (Mr 135 000) that is readily cleaved from the external portion of the a-subunit of glycoprotein lb by a calcium-and thiol-dependent protease (6, 7). Glycocaliciii circulates in normal plasma and increases in concentration during conditions associated with increased platelet activation and destruction in vivo (8, 9 ). An immunoradiometric assay (competitive binding assay) for glycocalicin in plasma was described by Coller et al. (8, 9 dure. These problems may be overcome by using enzyme immunoassays.
An enzyme-linked immunosorbent assay (ELISA) described previously for glycocalicin (10) was based on immunoinhibition;
however, it was used only for experimental studies and has not been validated clinically. 3 We describe here a noncompetitive, sandwich-type ELISA for quantifying glycocalicin in plasma by using two different monoclonal antibodies and the avidinbiotin technique (11, 12).
Materials and Methods Reagents
Diatube-H anticoagulant was obtained from Diagnos- mg/L, in 10 replicates in the same run, ranged from 3.6% to 5.2% (Table 1 ). The interassay CV ranged from 5.4% to 8.0%, estimated by determining glycocalicin in three plasma samples on 10 different occasions.
Analytical recovery.
To determine the analytical recovery of the assay, we assayed a plasma pool to which had been added concentrations of glycocalicin ranging from 0 to 1.0 mg/L. Recovery ranged from 88% to 100% (mean 96%) ( Table 2) .
Clinical applications. We measured the concentration of glycocalicin in plasma from healthy volunteers. In these subjects the mean value for glycocalicin was 0.36 (SD 0.07) mg/L, with a median value of 0.36 mgfL and a range of 0.25 to 0.54 mg/L (Table 3) . We also assayed plasma samples from patients with aplastic anemia (n = 2) and those with idiopathic thrombocytopenic purpura (n = 3). Plasma from the patients with aplastic anemia contained 0.02 and 0.01 mg/L of glycocalicin, whereas that from the patients with idiopathic thrombocytopenic purpura had a mean glycocalicin concentration of 0.34 mg/L (Table 3 ). Despite the low platelet count in the peripheral blood of both groups, the patients with aplastic anemia had the lower glycocalicin concentration.
The normal concentration of glycocalicin in the patients with idiopathic thrombocytopenic purpura indicates that this concentration does not simply reflect the peripheral platelet count, a finding that agrees with that of Steinberg et al. (9) .
DIscussIon
This is the first report on a noncompetitive ELISA for glycocalicin, a prot.eolytic fragment of platelet membrane glycoprotein Ib, in human plasma. The murmne monoclonal antibodies, HPL-7 and HPL-16, used in the present ELISA recognize two different sites on glycoprothin lb of the human platelet and show no cross-reactivity (16) (17) (18) . We used HPL-16 as the capture antibody and HPL-7 as the labeled antibody, antibodies having the highest titration for glycoprotein lb of the 12 clones of monoclonal anti-glycoprotein lb antibodies investigated (16) (17) (18) . Thus we were able to construct a noncompetitive sandwich-type ELISA of high specificity and sensitivity.
Avidin has an extraordinarily high affinity for biotin (affinity constant = 10 mol/L), and each avidin mol- antibody (11) . Thus, the avidin-biotin technique allows for heightened assay sensitivity. The use of this system in the present assay may contribute to both the high sensitivity (7 pg/L) and the relatively short performance time (2 h) of this quantitative method. The detection limit of the present ELISA (7 pg/L) was much lower (6.3% of the normal value) than that of previously published RIA for glycocalicin (8, 9). The determination range (0.01-1 mg/L) was also much wider than that of the RIA (6.3% to 100% of normal values). The intra-and interassay CVs (mean 4.3% and 7.0%, respectively) and analytical recovery (mean 96%) indmcate that the present ELISA is precise and accurate.
Microparticles derived from platelet membranes are present even in normal human plasma (24, 25) and might interfere with measurements of glycocalicin. Thus, it is very important to exclude platelet micropartides from plasma during sample preparation.
We found plasma obtained by centrifugation of blood at 3000 x g for 30 mm at 4#{176}C contained the same amount of glycocalicin as observed in plasma obtained at greater force. Although this centrifugal force to prepare plasma for glycocalicin might be insufficient to sediment all residual microparticles, there was no decrease in the concentration of glycocalicin even after ultracentrifugation (100000 x g for 60 mm). A previous study by Coller et al. (8) also showed that their standard centrifugation procedure (2000 x g for 10 mm) was enough to remove both platelets and platelet fragments. We thus conclude that centrifugation at 3000 xg for 30 mm is sufficient to obtain plasma for glycocalicmn determination by the present ELISA. In previous assays, glycocalicin was measured by RIA or enzyme immunoassay (8) (9) (10) 
